Connected Drug Delivery Devices Market Size & Growth Forecast 2027–2036, By Segments (Application, Product Type, Route of Administration), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growth Outlook
Connected Drug Delivery Devices Market size stood at USD 11.2 billion in 2026 and is predicted to grow at a 21.85% CAGR from 2027 to 2036, reaching USD 80.81 billion by 2036. The industry revenue for 2027 is estimated at USD 13.26 billion.
Get more details on this report
Request Free Sample ReportConnected Drug Delivery Devices Market Intelligence Snapshot
Regional Market Dynamics
- North America leads the market through strong adoption of digital healthcare, established reimbursement systems, and widespread integration of connected therapies into chronic disease management workflows.
- Asia Pacific is forecast to grow at a 24.97% CAGR as digital health adoption expands and healthcare providers increasingly deploy connected solutions for medication tracking and remote patient management.
Segment Momentum
- Diabetes Management accounted for 32.4% of the market in 2026, driven by the routine need for insulin delivery, dose tracking, adherence monitoring, and continuous patient engagement.
- Integrated Devices are expanding fastest because they combine drug delivery and connectivity in one system, simplifying treatment while enabling consistent data transmission and easier integration into routine care workflows.
Market Expansion Drivers
- Rising demand for remote patient monitoring accelerating adoption of connected medication devices.
- Increasing focus on medication adherence driving integration of smart dosing and reminder technologies.
- Strategic collaborations in digital diabetes management expanding connected drug delivery ecosystems.
Leading Market Participants
- Key players in the connected drug delivery devices market include Medtronic plc (Ireland), Teva Pharmaceutical Industries Ltd. (Israel), Koninklijke Philips N.V. (Netherlands), Ypsomed Holding AG (Switzerland), Biocorp Production S.A. (France), Propeller Health (United States), Adherium Limited (New Zealand), Amiko Digital Health Ltd. (Switzerland), Phillips-Medisize LLC (United States), Cohero Health Inc. (United States).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 11.2 billion
- 2027 Estimated Market Size: USD 13.26 billion.
- Projected Market Size: USD 80.81 billion by 2036
- Growth Forecast: 21.85% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Diabetes Management (Application) | Integrated Devices (Product Type) | Inhalational (Route of Administration)
- Emerging Opportunity Segment: Diabetes Management (Application) | Integrated Devices (Product Type) | Inhalational (Route of Administration)
Market Growth Drivers and Industry Trends
Rising demand for remote patient monitoring accelerating adoption of connected medication devices
The growing adoption of remote healthcare models is increasing the need for connected devices that allow healthcare professionals and patients to monitor treatment-related information outside traditional clinical settings. This trend will drive the connected drug delivery devices market growth as smart medication systems can transmit dosing information, usage data, and selected patient-related information through connected platforms. Remote monitoring can help clinicians gain greater visibility into treatment patterns while allowing patients to manage medication routines from home. The integration of connected delivery technologies with digital healthcare platforms is also supporting more continuous interaction between patients, caregivers, and healthcare providers.
Increasing focus on medication adherence driving integration of smart dosing and reminder technologies
Medication non-adherence remains an important challenge in the management of long-term therapies, creating demand for technologies that can help patients follow prescribed treatment schedules more consistently. The connected drug delivery devices market growth is supported by smart dosing and reminder functions that can provide alerts, record medication usage, and support structured treatment routines. Connected devices can also generate digital records that help patients and healthcare professionals identify missed or delayed doses and better understand treatment behavior. These capabilities are particularly relevant for chronic conditions where medication schedules may involve repeated or complex dosing requirements.
Strategic collaborations in digital diabetes management expanding connected drug delivery ecosystems
The increasing collaboration between healthcare technology providers, pharmaceutical stakeholders, and digital health platforms is supporting the development of more integrated diabetes management ecosystems. These collaborations will propel the connected drug delivery devices market growth by connecting medication delivery technologies with digital monitoring, patient engagement, and disease-management platforms. Integration can allow data generated through connected delivery devices to be incorporated into broader care workflows, supporting more coordinated management of treatment routines. The growing digitalization of diabetes care is also creating opportunities for connected delivery technologies to operate as part of comprehensive patient management systems.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Rising demand for remote patient monitoring accelerating adoption of connected medication devices | 2.00% | High | North America, Europe | High | Near Term |
| Increasing focus on medication adherence driving integration of smart dosing and reminder technologies | 1.90% | High | North America, Asia Pacific | High | Mid Term |
| Strategic collaborations in digital diabetes management expanding connected drug delivery ecosystems | 1.60% | Moderate | North America, Europe | Emerging | Long Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America (Largest Region)
The connected drug delivery devices market was anchored by North America, which held the largest share in 2026. Advanced healthcare infrastructure, strong adoption of digital health technologies, and increasing emphasis on patient-centric treatment are supporting demand for connected delivery solutions. Integration of monitoring and connectivity features is also strengthening their role in medication management and remote care.
Asia Pacific (Fastest-Growing Region)
Asia Pacific represents the fastest-growing regional market as healthcare systems increasingly adopt connected technologies and improve access to advanced drug delivery solutions. Rising digital health adoption, expanding healthcare infrastructure, and growing interest in remote patient monitoring are creating opportunities for wider deployment of connected drug delivery devices.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Precision Care AdoptionGermany emphasizes connected drug delivery devices that support structured disease management and secure health data exchange. Manufacturers focus on interoperable solutions aligned with digital healthcare initiatives while providers seek reliable patient adherence and therapy monitoring capabilities.
France 🇫🇷
Patient Monitoring FocusFrance supports connected drug delivery devices through initiatives that enhance chronic disease monitoring and coordinated patient care. Healthcare stakeholders increasingly value solutions that improve treatment compliance while fitting established clinical workflows.
Italy 🇮🇹
Home Therapy SupportItaly is expanding the use of connected drug delivery devices to strengthen home-based treatment and outpatient care. Device suppliers emphasize intuitive operation, remote follow-up, and improved medication adherence for patients managing long-term conditions.
Japan 🇯🇵
Aging Care ConnectivityJapan advances connected drug delivery devices to improve medication adherence among its aging population. Companies prioritize compact, user-friendly systems with remote monitoring functions that complement home-based care and long-term disease management programs.
South Korea 🇰🇷
Smart Health EcosystemSouth Korea integrates connected drug delivery devices with advanced digital health infrastructure and mobile healthcare platforms. Local innovation focuses on connected therapies, real-time patient engagement, and secure data sharing to improve treatment continuity.
United States 🇺🇸
Digital Therapeutics IntegrationThe U.S. prioritizes connected drug delivery devices that integrate with remote patient monitoring platforms and electronic health records. Healthcare providers and manufacturers emphasize adherence tracking, real-world data collection, and value-based care initiatives across chronic disease management.
Segment Leadership and Growth Trends
Connected Drug Delivery Devices Market Share (%), by Application, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportApplication Segment Analysis: Diabetes Management (Largest & Fastest-Growing Segment)
Diabetes management dominated the connected drug delivery devices market, accounting for 32.4% in 2026 while also representing the fastest-growing application. The segment benefits from the increasing need for consistent medication administration, treatment adherence, and individualized diabetes care. Connected delivery technologies can facilitate better coordination between medication use and digital health monitoring, helping support more informed disease management. Growing emphasis on remote care, connected health ecosystems, and patient-centric treatment approaches is further strengthening adoption.
Product Type Segment Analysis: Integrated Devices (Largest & Fastest-Growing Segment)
Integrated devices held the largest share of the connected drug delivery devices market in 2026 and are also expanding at the fastest pace. Their ability to combine drug delivery functionality with digital connectivity makes them well suited to healthcare models focused on treatment monitoring and patient engagement. Integrated solutions can support more streamlined medication management while reducing the need to coordinate separate devices. Increasing demand for connected therapies, personalized treatment, and digitally enabled healthcare is reinforcing their market position.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Application | Asthma, COPD, Diabetes Management, Others | Diabetes Management | Diabetes Management |
| Product Type | Standalone Components & Software, Integrated Devices | Integrated Devices | Integrated Devices |
| Route of Administration | Parenteral, Inhalational | Inhalational | Inhalational |
Competitive Landscape and Market Positioning
Top players in the connected drug delivery devices market:
1. Medtronic plc (Ireland)
2. Teva Pharmaceutical Industries Ltd. (Israel)
3. Koninklijke Philips N.V. (Netherlands)
4. Ypsomed Holding AG (Switzerland)
5. Biocorp Production S.A. (France)
6. Propeller Health (United States)
7. Adherium Limited (New Zealand)
8. Amiko Digital Health Ltd. (Switzerland)
9. Phillips-Medisize LLC (United States)
10. Cohero Health Inc. (United States)
The connected drug delivery devices market is evolving through deeper integration of digital monitoring and patient-centric delivery systems. Growing emphasis on treatment adherence and remote tracking is accelerating smart healthcare connectivity. Continuous development efforts are focused on improving usability while strengthening real-time data-driven treatment support.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| Medtronic plc (Ireland) | |||||||
| Teva Pharmaceutical Industries Ltd. (Israel) | |||||||
| Koninklijke Philips N.V. (Netherlands) | |||||||
| Ypsomed Holding AG (Switzerland) | |||||||
| Biocorp Production S.A. (France) | |||||||
| Propeller Health (United States) | |||||||
| Adherium Limited (New Zealand) | |||||||
| Amiko Digital Health Ltd. (Switzerland) | |||||||
| Phillips-Medisize LLC (United States) | |||||||
| Cohero Health Inc. (United States). |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Enable Injections | May-25 | Enable Injections received EU MDR CE mark approval for its enFuse Syringe Transfer System, enabling commercialization across European markets. The certification supports regulatory expansion of its large-volume subcutaneous delivery platform, strengthening the company’s position in advanced drug administration technologies and facilitating broader adoption of connected and patient-centric injectable delivery solutions. |
| Supernus Pharmaceuticals | Feb-25 | Supernus Pharmaceuticals received FDA approval for ONAPGO, a subcutaneous apomorphine infusion device for Parkinson’s motor fluctuations. The approval marks a significant commercialization milestone, expanding treatment options in neurological drug delivery and strengthening Supernus’s presence in device-enabled therapeutic solutions for chronic neurodegenerative disease management. |
| Gerresheimer | Dec-24 | Gerresheimer obtained FDA tentative approval for Lasix ONYU, a home-use furosemide micropump designed for congestive heart failure management. The development enhances Gerresheimer’s position in digitally enabled drug delivery systems, supporting the shift toward at-home infusion therapies and expanding its portfolio of connected and patient-managed drug delivery solutions. |
| Medtronic | Nov-24 | Medtronic received FDA clearance for its InPen app featuring missed-meal detection, integrated with its CGM ecosystem. The update strengthens Medtronic’s digital diabetes management portfolio by enhancing data-driven insulin dosing support, reinforcing its position in connected drug delivery ecosystems that integrate devices, sensors, and software platforms for chronic disease management. |
| Nemera | Sep-22 | Nemera inaugurated a new facility in Lyon, France, intended to serve as its European headquarters and innovation center. The site strengthens the company’s R&D and industrial capabilities in drug delivery device development, supporting broader commercialization of connected and advanced delivery systems through enhanced engineering, prototyping, and operational integration in Europe. |
| Propeller Health | May-20 | Propeller Health received FDA 510(k) clearance to connect Symbicort inhaler users to its digital health platform. The clearance enabled expanded integration of inhaled therapies with digital monitoring systems, strengthening Propeller’s role in connected respiratory care and improving patient adherence and outcome tracking in chronic respiratory disease management. |
| Aptar Pharma | Jan-20 | Aptar Pharma partnered with Lupin Limited to launch ADHERO, India’s first connected metered-dose inhaler add-on device. The solution enables real-time tracking of inhaler usage for respiratory patients, strengthening adherence monitoring capabilities and expanding Aptar Pharma’s presence in connected respiratory drug delivery solutions within emerging markets. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Connected Drug Delivery Devices Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| End User | Patients, Healthcare Providers, Caregivers, Pharmaceutical & Biopharmaceutical Companies |
| Healthcare Setting | Home Care, Hospitals, Outpatient Clinics, Specialty Care Centers |
| Reimbursement Model | Private Insurance, Public Insurance, Self-Pay, Employer-Sponsored Coverage |
Connected Drug Delivery Devices Market — Custom TOC
| Custom Chapter | Custom Details |
|---|---|
| Healthcare Provider Adoption and Workflow Readiness Analysis |
|
| Reimbursement and Digital Health Coverage Landscape |
|
| Priority Disease Area Expansion Opportunity Matrix |
|
Need a different cut of the data?
Request Custom ResearchHow large is the connected drug delivery devices market?
What is the anticipated CAGR of the connected drug delivery devices industry?
How is the expansion of remote patient monitoring shaping demand for connected drug delivery devices?
Why is integration between digital platforms and drug delivery devices accelerating diabetes care adoption?
Why does Diabetes Management lead the connected drug delivery devices market?
Why are Integrated Devices the fastest-growing product type in the connected drug delivery devices market?
Why does North America hold the largest share of the connected drug delivery devices market?
What is driving rapid growth in the connected drug delivery devices market across Asia Pacific?
Who holds a significant market share in the connected drug delivery devices landscape?
Our Clients
"The team took the time to understand our specific business needs and delivered a report that was well aligned with our objectives. Their expertise and understanding of the industry were clearly reflected in the quality and relevance of the insights provided."
Siemens Healthcare
"Our experience in acquiring the research report has been excellent. The depth of analysis, and actionable insights provided have been extremely valuable in supporting our ongoing R&D efforts."
GC Biopharma
"The report offered a comprehensive view of the market trends. The in-depth segmentation and analysis of emerging opportunities gave us a better understanding of the market."
Medtronic
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source | Reference |
|---|---|
| World Health Organization (WHO) | www.who.int |
| U.S. Food & Drug Administration (FDA) | www.fda.gov |
| European Medicines Agency (EMA) | www.ema.europa.eu |
| Centers for Disease Control and Prevention (CDC) | www.cdc.gov |
| National Institutes of Health (NIH) | www.nih.gov |
| National Center for Biotechnology Information (NCBI) | www.ncbi.nlm.nih.gov |
| PubMed | pubmed.ncbi.nlm.nih.gov |
| ClinicalTrials.gov | clinicaltrials.gov |
| International Organization for Standardization (ISO) | www.iso.org |
| ASTM International | www.astm.org |
| Advanced Medical Technology Association (AdvaMed) | www.advamed.org |
| Medical Device Innovation Consortium (MDIC) | mdic.org |
| Biotechnology Innovation Organization (BIO) | www.bio.org |
| International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) | www.ifpma.org |
| U.S. Pharmacopeia (USP) | www.usp.org |
| European Directorate for the Quality of Medicines & HealthCare (EDQM) | www.edqm.eu |
| World Organisation for Animal Health (WOAH) | www.woah.org |
| American Hospital Association (AHA) | www.aha.org |
| OECD Health | www.oecd.org/health |
| World Bank Data | data.worldbank.org |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization